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Abstract 
Background: Pioglitazone use is known to be associated with a reduced risk of recurrent stroke in patients with 
diabetes mellitus (DM) who have a history of stroke. However, it is unclear whether this benefit extends to patients 
without a history of stroke. We aimed to evaluate the association between pioglitazone use and development of first 
attack of ischemic stroke in patients with newly diagnosed type 2 DM.
Methods: Using longitudinal nationwide data from the 2002–2017 Korean National Health Insurance Service DM 
cohort, we analyzed the association between pioglitazone use and incidence of primary ischemic stroke using a 
nested case–control study. Among 128,171 patients with newly onset type 2 DM who were stroke‑free at the time 
of DM diagnosis, 4796 cases of ischemic stroke were identified and matched to 23,980 controls based on age, sex, 
and the onset and duration of DM. The mean (standard deviation) follow‑up time was 6.08 (3.34) years for the cases 
and controls. Odds ratios (ORs) and 95% confidence intervals (CIs) for the association between ischemic stroke and 
pioglitazone use were analyzed by multivariable conditional logistic regression analyses adjusted for comorbidities, 
cardiometabolic risk profile, and other oral antidiabetic medications.
Results: Pioglitazone use was associated with a reduced risk of first attack of ischemic stroke (adjusted OR [AOR] 0.69, 
95% CI 0.60–0.80) when compared with non‑use. Notably, pioglitazone use was found to have a dose‑dependent 
association with reduced rate of ischemic stroke emergence (first cumulative defined daily dose [cDDD] quartile AOR 
0.99, 95% CI 0.74–1.32; second quartile, AOR 0.77, 95% CI 0.56–1.06; third quartile, AOR 0.51, 95% Cl 0.36–0.71; highest 
quartile, AOR 0.48, 95% CI 0.33–0.69). More pronounced risk reduction was found in patients who used pioglitazone 
for more than 2 years. A further stratified analysis revealed that pioglitazone use had greater protective effects in 
patients with risk factors for stroke, such as high blood pressure, obesity, and current smoking.
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Background
Type 2 diabetes mellitus (DM) is associated with 
increased mortality, which is primarily attributable to 
cerebrovascular disease [1, 2]. In particular, the risk of 
stroke is three times higher in patients with DM than 
that in the general population [3, 4]. Insulin resistance, a 
pivotal pathogenic condition found in DM, plays a criti-
cal role in the development of ischemic stroke via aggra-
vation of atherosclerosis [5]. On the other hand, insulin 
resistance is also considered a modifiable risk factor in 
terms of stroke prevention [6].
Pioglitazone is an agonist of peroxisome prolifera-
tion activated receptor γ (PPAR-γ), and one of the most 
potent insulin-sensitizing drugs. Recent clinical trials 
have demonstrated its beneficial effects on cerebrovas-
cular outcomes by mitigating the progression of carotid 
intima-media thickness independent of glycemic control 
[7, 8]. Previous clinical studies have provided strong evi-
dence supporting the usefulness of pioglitazone for sec-
ondary stroke prevention [9, 10]. For instance, Kim et al. 
recently reported that treatment with pioglitazone sig-
nificantly lowered the risk of recurrent stroke in patients 
with DM and acute ischemic stroke [10].
Despite extensive experimental studies demonstrating 
the potential benefit of pioglitazone use in cerebrovascu-
lar risk, large-scale clinical studies are limited to patients 
with a history of previous stroke, and the preventive 
effects of pioglitazone use against primary ischemic 
stroke are often conflicting. Although the Prospec-
tive Pioglitazone Clinical Trial in Macrovascular Events 
(PROactive) revealed that treatment with pioglitazone 
contributed to a decreased risk of stroke compared with 
placebo in patients with type 2 DM with previous stroke 
history, there was no significant preventive effect of piogl-
itazone use on the development of stroke in a subgroup 
without prior stroke [11]. Another study reported that 
pioglitazone use for less than 3  years increased the risk 
of ischemic stroke in elderly patients with DM, whereas 
a recent retrospective study found that pioglitazone use 
prevented new-onset ischemic stroke in patients with 
DM who had cardiovascular risk factors [12, 13]. How-
ever, these previous studies were conducted only with 
participants who had cardiovascular risk factors such as 
hypertension or hyperlipidemia; hence, their generaliz-
ability is limited. There has been no report of such ben-
eficial effects of pioglitazone use against the first attack of 
ischemic stroke in the general population of patients with 
DM. In real-world practice, the effect of pioglitazone on 
stroke may vary according to different clinical character-
istics in patients taking the medication and its interaction 
with other glucose-lowering agents.
Therefore, we aimed to examine the preventive effect 
of pioglitazone use on first attack of ischemic stroke in 
a general DM population using a nested case–control 
design. To account for confounding effects by indication, 
we assessed the cardiometabolic risk profile and pre-
scription registry date of patients with newly diagnosed 
type 2 DM with no previous history of stroke.
Methods
Study design and data source
We used the 2002–2017 dataset from the Korean 
National Health Insurance Service (NHIS)-DM cohort. 
It contains data from 400,000 patients with type 2 DM, 
which corresponds to a sample of approximately 23% of 
the entire type 2 DM population in the 35–85-year age 
group in South Korea. This dataset includes all inpa-
tient and outpatient medical claims data, including data 
on prescription drug use, diagnostic and treatment 
codes, and primary and secondary diagnosis codes. It 
also includes the National Health Screening Program 
(NHSP) data. Since 2000, the Korean government has 
implemented an obligatory NHIS, which covers up to 
98% of the entire Korean population. All insured adults 
are eligible for the NHSP and are recommended to 
undergo a standardized health check-up every 1–2 years. 
The Korean NHIS claims database records diagnoses 
based on the International Statistical Classification of 
Disease and Related Health Problems, Tenth Revision 
(ICD-10) codes. This study was approved by the Institu-
tional Review Board of Yonsei University Health System 
(approval no. 4-2021-0127), and the approving authority 
waived the requirement for informed consent because of 
the use of deidentified patient data.
Selection of cases and controls
From the Korean NHIS-DM cohort, a total of 128,171 
patients with newly diagnosed DM (ICD E11) with no 
previous history of ischemic stroke, who had undergone 
a health check-up between 2004 and 2012 were enrolled, 
and follow-up data collected until December 2017 were 
reviewed. Ischemic stroke was diagnosed using ICD-10 
code I63. To ensure diagnostic accuracy, patients were 
defined as having ischemic stroke only when it was a 
Conclusions: Pioglitazone use may have a preventive effect on primary ischemic stroke in patients with type 2 DM, 
particularly in those at high risk of stroke.
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primary diagnosis code on admission and when they 
underwent brain computed tomography, magnetic reso-
nance imaging, or magnetic resonance angiography dur-
ing hospitalization because of the assumption that those 
with acute ischemic stroke should undergo brain imag-
ing [14]. We excluded (i) patients who had not used anti-
diabetic medications (n = 39,564); (ii) patients receiving 
insulin treatment for more than 30 days (n = 7,027); (iii) 
patients with the onset of any type of stroke (ICD I60–
I64) within 30 days of DM diagnosis (n = 1234); (iv) cases 
with no matching control (n = 235); (v) patients exposed 
to rosiglitazone during the study period (n = 13,291). 
Patients treated with rosiglitazone were excluded to 
avoid the confounding effect of rosiglitazone, another 
drug of the thiazolidinedione class withdrawn from the 
Korean market in 2010 due to increased cardiovascular 
risk concerns. The index date was defined as the date of 
ischemic stroke diagnosis. Control subjects were ran-
domly selected at a 1:5 ratio from the DM cohort at the 
time when the case subjects were selected and were 
matched based on age, sex, the time point of DM diag-
nosis, and DM duration using incident density sampling.
Exposure to pioglitazone
Patients with total prescriptions for pioglitazone of ≥ 90 
cumulative defined daily doses (cDDDs) after the onset of 
DM treatment were deemed pioglitazone users. This defi-
nition was applied for pioglitazone and other antidiabetic 
drugs including insulin, sulfonylurea, biguanide, dipepti-
dyl peptidase-4 inhibitor, and alpha-glucosidase as they 
may confound the data. To obtain the cDDD for each 
patient, we summed all the pioglitazone prescriptions 
dispensed during a defined period (i.e., from the onset of 
DM to the index date of the diagnosis of ischemic stroke) 
and then converted the quantity to the number of cDDDs 
according to the World Health Organization definition 
[15]. Pioglitazone exposure was described using three 
criteria: (i) ever-user; (ii) cDDD; and (iii) duration of the 
prescription. The cDDD and duration were classified by 
quartiles.
Potential confounders
We obtained information on selected comorbid condi-
tions from inpatient and outpatient hospital diagnoses. 
The incidence of hypertension, dyslipidemia, heart fail-
ure, arterial fibrillation, ischemic heart disease (IHD), 
and depression and the Adapted Diabetes Complica-
tions Severity Index (aDCSI) from DM diagnosis to the 
index date were estimated [16]. The Charlson Comorbid-
ity Index (CCI) was measured during the 1  year before 
the DM diagnosis. Fasting blood glucose levels, systolic 
blood pressure, diastolic blood pressure, total cholesterol 
levels, creatinine levels, body mass index (BMI; < 18.5, 
18.5–22.9, 23.0–25.0, and ≥ 25.0  kg/m2), smoking status 
(none, past, and current), alcohol consumption (low: < 1 
time/week, moderate: 1–4 times/week, and heavy: 5–7 
times/week), and physical activity (yes: ≥ 1 time/week; 
no: never) were measured as close as possible to the DM 
diagnosis date.
Statistical analyses
The characteristics of the study population were ana-
lyzed descriptively using the standardized mean differ-
ence (SMD). SMD values above 0.2 were regarded as a 
potential imbalance between the two groups [17]. Con-
ditional logistic regression analysis was conducted to 
investigate the association between pioglitazone use and 
ischemic stroke. We calculated the crude odds ratio (OR), 
adjusted OR (AOR), and 95% confidence interval (CI) 
for ischemic stroke between pioglitazone users and non-
users. The analyses were adjusted for the following vari-
ables: hypertension, dyslipidemia, atrial fibrillation, heart 
failure, CCI, aDCSI, depression, fasting blood glucose 
levels, systolic blood pressure, diastolic blood pressure, 
total cholesterol levels, creatinine levels, statin use, car-
diovascular medications (aspirin, statin, anticoagulant, 
antiplatelet, and antihypertension drugs), other antidia-
betic medications, BMI, alcohol and smoking habits, and 
physical activity. To further assess the potential influence 
of preexisting risk factors for stroke, such as age, sex, 
hypertension, dyslipidemia, atrial fibrillation, obesity, 
smoking, alcohol consumption, and no physical activity, 
we stratified the analyses to assess people with risk fac-
tors and without risk factors separately. We used incident 
density random sampling for our primary analysis; how-
ever, the random imbalance of covariates between piogl-
itazone users and non-users may have affected the main 
outcome. Hence, we further conducted propensity score-
matching (PSM) to control for covariate imbalance that 
could potentially lead to selection bias. We conducted 
PSM using the nearest neighbor matching method and 
baseline covariates in a 1:4 ratio. A p-value < 0.05 was 
considered significant. All statistical analyses were per-
formed using SAS software, version 9.4 (Cary, NC, USA).
Results
Study population
A total of 128,171 patients with newly diagnosed type 2 
DM with no history of stroke were included in the study. 
Of these patients, we identified 4,796 ischemic stroke 
cases and matched them with 23,980 controls (Fig.  1). 
Table  1 shows the baseline characteristics of the cases 
and controls. Age, sex, date of DM diagnosis, and DM 
duration did not differ between the cases and controls 
after incidence density sampling. Compared with con-
trols, cases were more likely to have hypertension, atrial 
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fibrillation, heart failure, and depression. They were also 
more likely to use antihypertensive, antiplatelet, antico-
agulant, and antiarrhythmic agents. The proportion of 
individuals with current smoking status and heavy alco-
hol intake was higher among cases than among controls. 
The individuals were less likely to be physically active.
Pioglitazone use and ischemic stroke development
The associations between pioglitazone use and ischemic 
stroke were evaluated using conditional logistic mod-
els (Table 2). During the study period, 246 patients with 
ischemic stroke (5.1%) and 1513 controls (6.3%) had used 
pioglitazone. In the univariate analysis, pioglitazone use 
was associated with lower odds for ischemic stroke (OR 
[CI], 0.79 [0.67–0.92]), compared with non-use. Upon 
conditional logistic regression analyses adjusted for med-
ical comorbidities and treatment with oral antidiabetic 
medication, we found that pioglitazone use was signifi-
cantly associated with a lower risk of primary ischemic 
stroke (adjusted OR 0.69, 95% CI, 0.60–0.80). Table  2 
shows that pioglitazone use for extended periods has 
dose–response relationships with lowering risk of first 
onset ischemic stroke (< 171.5 cDDDs, adjusted OR 0.99; 
95% CI, 0.74–1.32; 171.5–324 cDDDs, adjusted OR 0.77, 
95% CI, 0.56–1.06; 325–576 cDDDs, adjusted OR 0.51, 
95% CI, 0.36–0.71; ≥ 577 cDDDs, adjusted OR 0.48, 95% 
CI, 0.33–0.69). The greatest risk reduction was shown in 
pioglitazone users with the highest cDDDs (≥ 577) with 
an AOR of 0.48 (95% CI, 0.33–0.69), compared with non-
users. Further investigation into the effect of duration of 
pioglitazone use showed a significant reduction in stroke 
risk in patients who used pioglitazone for 2 years or more 
(Table 3).
The protective effect of pioglitazone on first stroke 
was more evident in people at risk for stroke
The effect of pioglitazone use on the risk of primary 
stroke was evaluated in a subsequent stratified analy-
sis (Fig. 2). Pioglitazone use remained to be associated 
with a lower risk of stroke regardless of age, sex, DM 
duration, other medical comorbidities, and lifestyle risk 
factors, such as cigarette smoking, alcohol consump-
tion, and physical activity. Of note, pioglitazone was 
shown to have a greater protective effect in patients 
with a higher risk of stroke, such as those with hyper-
tension, IHD, longer duration of DM, obesity, current 
smoking, alcohol consumption, and no physical activ-
ity. These findings suggest that the beneficial effect of 
pioglitazone is more prominent for patients with DM 
with a higher risk of stroke. The subgroup analyses, 
which were conducted according to use of different 
medications, did not disclose any significant alteration 
Fig. 1 Flow chart of the study design
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in the observed effect of pioglitazone except on anti-
platelets (Additional file 1: Table S1, Figure S1).
Sensitivity analyses
A total of 4006 patients with ischemic stroke and 
15,398 without ischemic stroke were matched in a 
1:4 ratio. The demographic characteristics of the two 
cohorts were similar (Additional file 1: Table S2). After 
matching, the pioglitazone users still exhibited a signif-
icantly lower risk of primary ischemic stroke than did 
non-users (AOR 0.70, 95% CI, 0.58–0.84, Additional 
file 1: Table S3).
Discussion
In this national, longitudinal nested case–control study, 
we evaluated 4,796 ischemic stroke cases and 23,980 
control cases with matching variables including age, 
sex, time of DM diagnosis, and DM duration at a 1:5 
ratio from the NHIS-DM cohort. We found that piogl-
itazone use was significantly associated with a reduced 
risk of primary ischemic stroke in patients with newly 
diagnosed DM. Of note, the protective effect of piogl-
itazone on incident ischemic stroke was greater in 
patients with known stroke risk factors, including 
hypertension, obesity, smoking, and no physical activ-
ity. These findings suggest that the increased risk of 
ischemic stroke in patients with DM might be weak-
ened by pioglitazone use. To the best of our knowledge, 
this is the first large-scale population study to assess 
the efficacy of pioglitazone for primary stroke preven-
tion in Asian patients newly diagnosed with DM.







n (%) n (%)
Age 61.88 ± 8.98 61.88 ± 8.98  < 0.001
Women 2034 (42.4) 10,170 (42.4)  < 0.001
Diabetes duration (years) 6.08 ± 3.34 6.08 ± 3.34 0.001
 < 5 years 1929 (40.2) 9633 (40.2)
 5–10 years 2175 (45.4) 10,876 (45.4)
 ≥ 10 years 692 (14.4) 3471 (14.5)
BMI 0.035
 < 18.5 kg/m2 59 (1.2) 210 (0.9)
 18.5–22.9 kg/m2 1002 (20.9) 5036 (2.10)
 23–25 kg/m2 1185 (24.7) 6008 (25.1)
 ≥ 25 kg/m2 2550 (53.2) 12,726 (47.76)
Fasting blood glucose (mg/
dL)a
138.54 ± 53.91 134.89 ± 47.76 0.072
BP (mmHg)a
 Systolic 134.92 ± 17.91 132.38 ± 17.04 0.146
 Diastolic 82.14 ± 11.37 80.83 ± 10.74 0.118
Total cholesterol (mg/dL)a 205.23 ± 42.81 203.90 ± 41.61 0.032
Creatinine (mg/dL)† 1.02 ± 0.86 1.03 ± 0.95 0.005
Hypertension 3922 (81.8) 17,998 (78.1) 0.164
Atrial fibrillation 339 (7.1) 728 (3.0) 0.185
Ischemic heart disease 1269 (26.5) 5571(23.2) 0.075
Heart failure 732 (15.3) 2552 (10.6) 0.138
Dyslipidemia 2,446 (51.0) 13,484 (56.2) 0.105
CCI 0.03
 0 1442 (30.1) 7059 (29.4)
 1 1156 (24.1) 5583 (23.3)
 2 2198 (45.8) 11,338 (47.3)
aDCSI 0.147
 0 4175 (87.1) 21,951 (91.5)
 1 445 (9.3) 1402 (5.8)
 2 176 (3.7) 627 (2.6)
Depression 663 (13.8) 2,969 (12.4) 0.043
Medication
 Statin 2589 (54.0) 13,445 (56.1) 0.042
 Aspirin 2788 (58.1) 12,741 (53.1) 0.101
 Antiplatelet 961 (20.0) 2991 (12.5) 0.206
 Anticoagulant 204 (4.3) 438 (1.8) 0.142
 Antihypertensive agents 3551 (74.0) 16,150 (67.3) 0.147
 Antiarrhythmic agents 551 (11.5) 2188 (9.1) 0.078
Antidiabetic medication
 Biguanide 3813 (79.5) 17,598 (73.4) 0.145
 Alpha‑glucosidase inhibitors 411 (8.6) 1716 (7.2) 0.053
 DPP‑ IV inhibitors 1220 (25.4) 4721 (19.7) 0.138
 Insulin 1983 (41.3) 5177 (21.6) 0.435
 SGLT2 inhibitors 47 (1.0) 174 (0.7) 0.028
 Sulfonylurea 3550 (74.0) 15,972 (66.6) 0.163
Smoking
aDCSI adapted Diabetes Complication Severity Index, BP blood pressure, CCI 
Charlson Comorbidity Index, DPP-IV dipeptidyl peptidase IV, SGLT2 sodium-
glucose co-transporter 2, SMD Standardized mean difference








n (%) n (%)
 None 2963 (61.8) 15,772 (65.8) 0.154
 Past 570 (11.9) 3399 (14.2)
 Current 1263 (26.3) 4809 (20.1)
Alcohol use 0.056
 Low 3497 (72.9) 17,561 (73.2)
 Moderate 953 (19.9) 5002 (20.9)
 Heavy 346 (7.2) 1417 (5.9)
Physical activity 0.121
 Yes (≥ 1 time per week) 3182 (66.3) 17,244 (71.9)
Page 6 of 10Ha et al. Cardiovasc Diabetol          (2021) 20:152 
Previous studies on the cardiovascular effects 
of pioglitazone
Identifying the patients most likely to benefit from pre-
ventive care is a form of personalized medicine that is 
receiving attention in patient care. Previous studies found 
a protective effect of pioglitazone against recurrent stroke 
in patients with DM and prior stroke/ischemic attack. 
In the PROactive study, the stroke risk was reduced by 
47% [11], and the Insulin Resistance Intervention After 
Stroke trial found that pioglitazone reduced the risk of 
ischemic events by 24% [9]. However, the association 
between pioglitazone use and its protective effect in 
Table 2 Reduced ischemic stroke risk associated with pioglitazone use in diabetes mellitus patients
AOR adjusted odds ratio, cDDDs cumulative defined daily doses, CI confidence interval, Q quartile
* Analysis was adjusted for the following covariates: hypertension, ischemic heart disease, dyslipidemia, Charlson Comorbidity Index, Diabetes Complications Severity 
Index, depression, statin use, aspirin use, antiplatelet use, anticoagulant use, antihypertensive drug use, antiarrhythmic drug use, use of antidiabetic medications, 
fasting blood glucose levels, systolic blood pressure, diastolic blood pressure, total cholesterol levels, creatinine levels, body mass index, smoking status, alcohol 





Crude OR (95% Cl) p-value AOR (95% Cl)* p-value
n (%) n (%)
Pioglitazone use
 Never user 4550 (94.9) 22,467 (93.7) 1 (reference) 1 (reference)
 Users 246 (5.1) 1513 (6.3) 0.79 (0.67–0.92) 0.002 0.69 (0.59–0.80)  < 0.0001
Cumulative dose of use
 Never user 4550 (94.9) 22,467 (93.7) 1 (reference) 1 (reference)
 Ever‑user
  Q1 (< 171.5 cDDDs) 85 (1.8) 356 (1.5) 1.17 (0.89–1.53) 0.253 0.99 (0.74–1.32) 0.938
  Q2 (171.5–324 cDDDs) 68 (1.4) 371 (1.5) 0.90 (0.67–1.20) 0.469 0.77 (0.56–1.06) 0.103
  Q3 (325–576 cDDDs) 50 (1.0) 390 (1.6) 0.63 (0.46–0.87) 0.005 0.50 (0.36–0.70)  < 0.001
  Q4 (≥ 577 cDDDs) 43 (0.9) 396 (1.7) 0.50 (0.36–0.71)  < 0.001 0.48 (0.33–0.69)  < 0.001
Table 3 Relationship of pioglitazone use to primary ischemic stroke stratified by duration of pioglitazone use in patients with type 2 
diabetes
AOR adjusted odds ratio, CI confidence interval, Q quartile
* Analysis was adjusted for the following covariates: hypertension, ischemic heart disease, dyslipidemia, Charlson Comorbidity Index, Diabetes Complications Severity 
Index, depression, statin use, aspirin use, antiplatelet use, anticoagulant use, antihypertensive drug use, antiarrhythmic drug use, use of antidiabetic medications, 
fasting blood glucose levels, systolic blood pressure, diastolic blood pressure, total cholesterol levels, creatinine levels, body mass index, smoking status, alcohol 





Crude OR (95% Cl) p-value AOR (95% Cl)* p-value
n (%) n (%)
Duration of use (days, quartile)
 Never user 4,550 (94.9) 22,467 (93.7) 1 (reference) 1 (reference)
 Ever‑user
  Q1 (< 336 days) 84 (1.8) 354 (1.5) 1.15 (0.88–1.51) 0.253 0.96 (0.72–1.29) 0.807
  Q2 (227–630 days) 68 (1.4) 364 (1.5) 0.93 (0.70–1.25) 0.469 0.78 (0.57–1.07) 0.220
  Q3 (631–1,129 days) 55 (1.2) 394 (1.6) 0.68 (0.50–0.92) 0.005 0.54 (0.39–0.75)  < 0.001
  Q4 (≥ 1,130 days) 39 (0.8) 401 (1.7) 0.46 (0.32–0.65)  < 0.001 0.45 (0.31–0.65)  < 0.001
Duration of use (years)
 Never user 4550 (94.9) 22,467 (93.7) 1 (reference) 1 (reference)
 Ever‑user
  Less than 1 year 91 (1.9) 410 (1.7) 1.08 (0.83–1.40) 0.253 0.91 (0.69–1.19) 0.480
  1–2 years 75 (1.6) 425 (1.8) 0.86 (0.65–1.14) 0.469 0.72 (0.53–0.97) 0.028
  2–3 years 37 (0.8) 260 (1.1) 0.72 (0.50–1.05) 0.005 0.56 (0.38–0.84) 0.004
  More than 3 years 43 (0.9) 418 (1.7) 0.48 (0.34–0.67)  < 0.001 0.46 (0.32–0.67)  < 0.001
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primary stroke prevention in patients with DM was not 
clearly understood. In the PROactive study, there was no 
preventive effect against the development of stroke (HR 
1.06; 95% CI 0.73–1.52, p = 0.767) [11]. Another pop-
ulation-based study in Taiwan also reported no protec-
tive effects of pioglitazone on ischemic stroke prevention 
[18]. However, these results should be interpreted care-
fully since they have short pioglitazone exposure peri-
ods of less than 5 years; the mean follow-up period was 
2.9  years for the PROactive study and 672  days for the 
Taiwanese study. According to our results, the protective 
effect of pioglitazone against primary stroke increased 
with cDDD, and there was a significantly reduced risk in 
people with a DM duration of more than 10 years. This 
suggests that the effect of pioglitazone against primary 
stroke may not have been clearly revealed in the previous 
randomized controlled trials due to their short follow-up 
periods.
Recently, the effect of pioglitazone on stroke has been 
expanded to prediabetes or patients without a history of 
stroke. In the prediabetic population, good adherence 
to pioglitazone had a HR of 0.64 for stroke compared to 
placebo [19]. In a population-based study of 7,574 piogl-
itazone users and 32,337 non-pioglitazone users from 
the National Health Insurance Research Database, those 
who used pioglitazone has a lower risk of ischemic stroke 
(HR 0.78; 95% CI: 0.62–0.95) [12]. However, the study 
population was limited to patients with DM who had at 
least one cardiovascular risk factor, i.e., hyperlipidemia or 
hypertension, which may have caused selection bias. In 
this study, we found that pioglitazone use has a favorable 
effect on decreasing the risk of primary ischemic stroke 
in patients with newly diagnosed DM. In addition, the 
preventive impact was particularly significant with a high 
cDDD of pioglitazone use, or in patients with comorbid 
stroke risk factors, i.e., hypertension, IHD, obesity, smok-
ing, alcohol use, and no physical activity.
There are concerns about the adverse effects of piogl-
itazone, such as increased fluid retention, weight gain, 
and heart failure [20]. Since the evidence is still equivo-
cal, this may have affected the decision of physicians 
to actively prescribe the drug. However, recent stud-
ies reported that those risks may be minimized by low-
ering the dosage [21] or through combination therapy 
with a sodium-glucose co-transporter-2 (SGLT2) inhibi-
tor or glucagon-like peptide -1 (GLP1) receptor agonist 
[22–24]. Pioglitazone added to metformin as a second-
ary oral antidiabetic agent has been reported to reduce 
the cardiovascular risk in patients with DM compared 
with sulfonylurea added to metformin [25]. Considering 
Fig. 2 Odds ratios for ischemic stroke in the different subgroups of pioglitazone users. Boxes indicate the adjusted odds ratio (OR), and limit lines 
indicate the 95% confidence interval (CI). DM, diabetes mellitus
Page 8 of 10Ha et al. Cardiovasc Diabetol          (2021) 20:152 
that most patients with DM receive additional medica-
tion other than metformin, pioglitazone, which is now 
generically available, may present a more affordable cost-
effective cardioprotective option than SGLT2 inhibitor or 
GLP1 receptor agonist [26]. Clinical studies have shown 
no reduction or a slight reduction in major cardiovascu-
lar or cerebrovascular events through intensive glycemic 
control [27]. Rather, treatment of preexisting traditional 
cerebrovascular risk factors has consistently been asso-
ciated with major cerebrovascular benefits in patients 
with DM [28–32]. Therefore, our results may provide an 
armamentarium to physicians committed to cardiovas-
cular prevention in patient care and a rationale for using 
pioglitazone in patients at high risk of stroke.
Mechanism of cardiovascular protection by pioglitazone
The exact mechanism underlying the association 
between pioglitazone use and reduced cardiovascular 
risk is uncertain. Thiazolidinediones are insulin-sen-
sitizing antidiabetics agents that act through PPAR-γ 
to cause a durable improvement in glycemic control in 
patients with type 2 DM [33, 34]. In addition to glycemic 
control, pioglitazone also has a favorable effect on the 
plasma lipid profile; it reduces the levels of triglyceride 
and free fatty acid and increases the levels of high-den-
sity lipoprotein cholesterol [35]. More importantly, since 
PPAR-γ receptors are expressed in endothelial cells, arte-
rial smooth muscle cells, and monocytes/macrophages, 
pioglitazone exerts direct anti-atherogenic effects on the 
arterial wall and has a direct anti-inflammatory and anti-
oxidant effect against ischemic injury while also promot-
ing neuronal regeneration [36–39]. A recent discovery 
suggests that pioglitazone may improve memory impair-
ment by increasing low-density lipoprotein related recep-
tor protein expression in the hippocampus, indicating 
that the effect of pioglitazone may extend to neuropro-
tection [40].
Limitations
As this study was a population-based nested case–con-
trol study using a claims database, there were several 
limitations. The patients included in this study may not 
have taken their prescribed medication or the dose pre-
scribed, leading to exposure misclassification. Although 
adjustment was made for various potential confound-
ing parameters including baseline laboratory data, other 
glucose-lowering agents, and lifestyle information in the 
analyses, data on the severity of index stroke and hemo-
globin A1c levels, which are strong prognostic factors 
in stroke patients, were not collected due to the lack of 
detailed clinical information. However, we further evalu-
ated the interaction between pioglitazone and known 
risk factors and provided evidence that pioglitazone 
may be beneficial to people at risk. This was an obser-
vational study, not a randomized trial, and, therefore, 
we should also consider the possibility of hidden bias 
between patients who received pioglitazone and those 
who did not. Despite adjustment for some differences in 
baseline characteristics, residual unidentified confound-
ers may influence the relationship between pioglitazone 
use and stroke risk. In this study, only a small propor-
tion of patients received pioglitazone, which could result 
in biased estimates. Although administrative databases 
are increasingly used for clinical research, such studies 
are potentially susceptible to measurement errors aris-
ing from coding inaccuracies. To mitigate this weakness, 
we applied the definition that was validated from previ-
ous studies using the Korean NHIS cohort [10]. Lastly, 
we were unable to evaluate the potential adverse effects 
of pioglitazone such as weight gain, fluid retention, and 
fracture. Although we reported that there is a reduced 
risk of stroke according to the cDDD of pioglitazone, 
further research is needed to find the optimal dose that 
minimizes drug-related adverse events in addition to 
potential benefits. In addition, a large-scale prospective 
study is necessary to determine the long-term drug safety 
profile of pioglitazone.
Conclusion
We found that pioglitazone use dose-dependently 
reduces the risk of primary ischemic stroke in patients 
with DM, particularly in individuals with a high risk of 
stroke. Large, prospective clinical studies are warranted 
to confirm the efficacy of pioglitazone use on preven-
tion of primary ischemic stroke in patients with DM, 
especially in those who have additional risk factors of 
ischemic stroke.
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